A network meta-analysis of the efficacy and side effects of udca-based therapies for primary sclerosing cholangitis

Oncotarget

Volumn 6, Issue 29, 2015, Pages 26757-26769

  Zhu, Gui Qi ^a,b   Shi, Ke Qing ^a,b   Huang, Gui Qian ^a,b   Wang, Li Ren ^a,b   Lin, Yi Qian ^a,b   Braddock, Martin ^c   Chen, Yong Ping ^a,b   Zhou, Meng Tao ^a   Zheng, Ming Hua ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Adverse events; Clinical efficacy; Intervention; Network meta analysis; Pathology Section; Primary sclerosing cholangitis

Indexed keywords

ALKALINE PHOSPHATASE; BILIRUBIN; METRONIDAZOLE; MYCOPHENOLATE MOFETIL; URSODEOXYCHOLIC ACID; CHOLAGOGUE; MYCOPHENOLIC ACID;

ARTICLE; BILIRUBIN BLOOD LEVEL; COMPARATIVE EFFECTIVENESS; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; HISTOLOGY; HUMAN; LIVER TRANSPLANTATION; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PRIMARY SCLEROSING CHOLANGITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; ADULT; AGED; ANALOGS AND DERIVATIVES; BLOOD; CHOLANGITIS, SCLEROSING; LIVER; METHODOLOGY; MIDDLE AGED; ODDS RATIO; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ALKALINE PHOSPHATASE; BILIRUBIN; CHOLAGOGUES AND CHOLERETICS; CHOLANGITIS, SCLEROSING; DISEASE PROGRESSION; HUMANS; LIVER; LIVER TRANSPLANTATION; METRONIDAZOLE; MIDDLE AGED; MYCOPHENOLIC ACID; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID; YOUNG ADULT;

EID: 84944457938     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5610     Document Type: Article

References (48)

1. Angulo P, Lindor KD. Primary sclerosing cholangitis. Hepatology (Baltimore, Md.). 1999;30:325-332.
2. Mahdavinia M, Mirsaeidi M, Bishehsari F, McGrath K. Primary sclerosing cholangitis in common variable immune deficiency. Allergology international: official journal of the Japanese Society of Allergology. 2015;64:187-189.
3. Wiesner RH. Current concepts in primary sclerosing cholangitis. Mayo Clinic proceedings. 1994;69:969-982.
4. Sheng R, Zajko AB, Campbell WL, Abu-Elmagd K. Biliary strictures in hepatic transplants: prevalence and types in patients with primary sclerosing cholangitis vs those with other liver diseases. AJR. American journal of roentgenology. 1993;161:297-300.
5. Arnelo U, von Seth E, Bergquist A. Prospective evaluation of the clinical utility of single-operator peroral cholangioscopy in patients with primary sclerosing cholangitis. Endoscopy. 2015; 47:696-702.
6. Venkat VL, Ranganathan S, Mazariegos GV, Sun Q, Sindhi R. Recurrence of primary sclerosing cholangitis in pediatric liver transplant recipients. Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2014;20:679-686.
7. Gow PJ, Chapman RW. Liver transplantation for primary sclerosing cholangitis. Liver. 2000;20:97-103.
8. Othman MO, Dunkelberg J, Roy PK. Urosdeoxycholic acid in primary sclerosing cholangitis: a meta-analysis and systematic review. Arab journal of gastroenterology: the official publication of the Pan-Arab Association of Gastroenterology. 2012;13:103-110.
9. Poropat G, Giljaca V, Stimac D, Gluud C. Bile acids for primary sclerosing cholangitis. The Cochrane database of systematic reviews. 2011:Cd003626.
10. Shi J, Li Z, Zeng X, Lin Y, Xie WF. Ursodeoxycholic acid in primary sclerosing cholangitis: meta-analysis of randomized controlled trials. Hepatology research: the official journal of the Japan Society of Hepatology. 2009;39:865-873.
11. Triantos CK, Koukias NM, Nikolopoulou VN, Burroughs AK. Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis. Alimentary pharmacology & therapeutics. 2011;34:901-910.
12. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ. Diagnosis and management of primary sclerosing cholangitis. Hepatology (Baltimore, Md.). 2010;51:660-678.
13. Angulo P, Batts KP, Jorgensen RA, LaRusso NA, Lindor KD. Oral budesonide in the treatment of primary sclerosing cholangitis. The American journal of gastroenterology. 2000;95:2333-2337.
14. Javett SL. Azathioprine in primary sclerosing cholangitif. Lancet. 1971;1:810.
15. Knox TA, Kaplan MM. A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology. 1994;106:494-499.
16. Lindor KD, Jorgensen RA, Anderson ML, Gores GJ, Hofmann AF, LaRusso NF. Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study. The American journal of gastroenterology. 1996;91:511-515.
17. Lindor KD, Wiesner RH, Colwell LJ, Steiner B, Beaver S, LaRusso NF. The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. The American journal of gastroenterology. 1991;86:57-61.
18. Van Thiel DH, Carroll P, Abu-Elmagd K, Rodriguez-Rilo H, Irish W, McMichael J, Starzl TE. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. The American journal of gastroenterology. 1995;90:455-459.
19. Wagner A. Azathioprine treatment in primary sclerosing cholangitis. Lancet. 1971;2:663-664.
20. Conti F, Morelon E, Calmus Y. Immunosuppressive therapy in liver transplantation. Journal of hepatology. 2003;39:664-678.
21. Jorgensen KK, Lindstrom L, Cvancarova M, Karlsen TH, Castedal M, Friman S, Schrumpf E, Foss A, Isoniemi H, Nordin A, Holte K, Rasmussen A, Bergquist A, et al. Immunosuppression after liver transplantation for primary sclerosing cholangitis influences activity of inflammatory bowel disease. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association. 2013;11:517-523.
22. Sterling RK, Salvatori JJ, Luketic VA, Sanyal AJ, Fulcher AS, Stravitz RT, Contos MJ, Mills AS, Shiffman ML. A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis. Alimentary pharmacology & therapeutics. 2004;20:943-949.
23. Farkkila M, Karvonen AL, Nurmi H, Nuutinen H, Taavitsainen M, Pikkarainen P, Karkkainen P. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology (Baltimore, Md.). 2004;40:1379-1386.
24. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published metaanalyses. Bmj. 2003;326:472.
25. Ades AE, Sculpher M, Sutton A, Abrams K, Cooper N, Welton N, Lu G. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics. 2006;24:1-19.
26. Sutton A, Ades AE, Cooper N, Abrams K. Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics. 2008;26:753-767.
27. Beuers U, Spengler U, Kruis W, Aydemir U, Wiebecke B, Heldwein W, Weinzierl M, Pape GR, Sauerbruch T, Paumgartner G. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology (Baltimore, Md.). 1992;16:707-714.
28. De Maria N, Colantoni A, Rosenbloom E, Van Thiel DH. Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period. Hepato-gastroenterology. 1996;43:1472-1479.
29. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. The New England journal of medicine. 1997;336:691-695.
30. Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, Mooney J, Sargeant C, Braaten J, et al. Highdose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology (Baltimore, Md.). 2009;50:808-814.
31. Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology. 2001;121:900-907.
32. Olsson R, Boberg KM, de Muckadell OS, Lindgren S, Hultcrantz R, Folvik G, Bell H, Gangsoy-Kristiansen M, Matre J, Rydning A, Wikman O, Danielsson A, Sandberg-Gertzen H, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology. 2005;129:1464-1472.
33. Sinakos E, Marschall HU, Kowdley KV, Befeler A, Keach J, Lindor K. Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression. Hepatology (Baltimore, Md.). 2010;52:197-203.
34. Stiehl A, Walker S, Stiehl L, Rudolph G, Hofmann WJ, Theilmann L. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. Journal of hepatology. 1994;20:57-64.
35. Chen W, Gluud C. Bile acids for primary sclerosing cholangitis. The Cochrane database of systematic reviews. 2003:Cd003626.
36. Chen W, Liu J, Gluud C. Bile acids for viral hepatitis. The Cochrane database of systematic reviews. 2007:Cd003181.
37. Gordon FD. Primary sclerosing cholangitis. The Surgical clinics of North America. 2008;88:1385-1407, x.
38. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336-341.
39. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Bmj. 2011;343:d5928.
40. Lee MD. On the Complexity of Additive Clustering Models. Journal of mathematical psychology. 2001;45:131-148.
41. Dias S, Welton NJ, Sutton AJ, Ades AE. Evidence synthesis for decision making 1: introduction. Medical decision making: an international journal of the Society for Medical Decision Making. 2013;33:597-606.
42. Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Medical decision making: an international journal of the Society for Medical Decision Making. 2013;33:607-617.
43. Woods BS, Hawkins N, Scott DA. Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial. BMC medical research methodology. 2010;10:54.
44. Zhu GQ, Shi KQ, Huang S, Huang GQ, Lin YQ, Zhou ZR, Braddock M, Chen YP, Zheng MH. Network Meta-Analysis of Randomized Controlled Trials: Efficacy and Safety of UDCA-Based Therapies in Primary Biliary Cirrhosis. Medicine. 2015;94:e609.
45. Zhu GQ, Shi KQ, Huang S, Wang LR, Lin YQ, Huang GQ, Chen YP, Braddock M, Zheng MH. Systematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy. Alimentary pharmacology & therapeutics. 2015;41:624-635.
46. Zhu GQ, Shi KQ, You J, Zou H, Lin YQ, Wang LR, Braddock M, Chen YP, Zheng MH. Systematic review with network meta-analysis: adjuvant therapy for resected biliary tract cancer. Alimentary pharmacology & therapeutics. 2014;40:759-770.
47. Zhu GQ, You J, Shi KQ, He SY, Wang LR, Chen YP, Braddock M, Zheng MH. Systematic review with network meta-analysis: adjuvant chemotherapy for resected colorectal liver metastases. Medicine. 2015;94:e379.
48. Shriner D, Yi N. Deviance Information Criterion (DIC) in Bayesian Multiple QTL Mapping. Computational statistics & data analysis. 2009;53:1850-1860.